Drs. Kwok, Okada, Costello, and Mr. Stevers are developing an "off-the-shelf" cancer vaccine platform designed to eliminate aggressive solid tumors like glioblastoma and prevent them from returning. Where traditional therapies often fail because they target highly variable mutations unique to only parts of a tumor, this technology targets stable, systematic RNA splicing errors that are expressed uniformly across the entire tumor mass and shared among patients. With high-fidelity targeting, their immunotherapy stands to transform public cancer therapy by combining the precision of personalized medicine with global scalability.
